However, the phase 3 open-label CAURAL trial investigated osimertinib plus durvalumab versus osimertinib monotherapy in patients with EGFR-TKI sensitizing and EGFR T790M mutation-positive advanced NSCLC and disease progression after EGFR-TKI therapy45. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.